BPC-157 acts on VEGFR2/NO pathways; TB-500 acts on actin sequestration. Two independent mechanisms — the reason they are often studied together.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric juice fragment | Thymosin β4 fragment |
| Length | 15 residues | Bioactive fragment of 43-mer |
| Primary mechanism | VEGFR2 / NO signalling | Actin sequestration |
| Research use case | Vascular and mucosal models | Cytoskeletal and tissue models |
The two compounds are frequently combined in research (see the 'Wolverine' blend reference) because their mechanisms do not overlap.
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
